南非COVID-19疫苗接种规划的成本效果分析
本研究从公共支付者视角回顾性评估南非2021年2月至2023年1月COVID-19疫苗接种规划的成本效果,与无接种情景比较。结果显示,9个月和24个月时间跨度内每避免一个伤残调整生命年(DALY)的增量成本效果比(ICER)分别为1600美元和1300美元;将超额死亡纳入分析后分别降至1070美元和660美元。概率敏感性分析中近100%模拟低于南非基于机会成本的成本效果阈值(每避免一个DALY 2300美元)。作者认为该规划头两年具有良好成本效益。
要点
- 9个月时间跨度ICER为每避免一个DALY 1600美元。
- 24个月时间跨度ICER为每避免一个DALY 1300美元。
- 纳入85%超额死亡后ICER分别降至1070和660美元。
核心结论
- 研究结果表明南非COVID-19疫苗接种规划在实施头两年具有良好成本效益。
研究设计与样本
- 从公共支付者视角,将COVID-19疫苗接种规划与无接种情景比较,建立成本与健康结果模型。
- 成本以2021年美元表示,评估两个时间跨度:9个月(2021年2月至11月)和24个月(2021年2月至2023年1月)。
- 健康结果由以COVID-19相关住院和死亡数据参数化的疾病传播模型估计,并转换为伤残调整生命年(DALY)。
- 开展确定性和概率敏感性分析(DSA和PSA)以评估参数不确定性。
主要发现
- 第一个研究时间跨度ICER估计为每避免一个DALY 1600美元。
- 第二个研究时间跨度ICER估计为每避免一个DALY 1300美元。
- 当分析纳入这些时期所有超额死亡的85%时,第一和第二个研究时间跨度ICER分别估计为每避免一个DALY 1070美元和660美元。
- 在PSA中,近100%的模拟低于南非基于机会成本估计的成本效果阈值(每避免一个DALY 2300美元)。
- COVID-19疫苗接种规划每剂成本对ICER影响最大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 vaccines were rolled out in South Africa beginning in February 2021. In this study we retrospectively assessed the cost-effectiveness of the vaccination programme in its first two years of implementation. METHOD: We modelled the costs, expressed in 2021 US$, and health outcomes of the COVID-19 vaccination programme compared to a no vaccination programme scenario. The study was conducted from a public payer's perspective over two time-horizons - nine months (February to November 2021) and twenty-four months (February 2021 to January 2023). Health outcomes were estimated from a disease transmission model parameterised with data on COVID-19-related hospitalisations and deaths and were converted to disability adjusted life years (DALYs). Deterministic and probabilistic sensitivity analyses (DSA and PSA) were conducted to assess parameter uncertainty. RESULTS: Incremental cost-effectiveness ratio (ICER) was estimated at US$1600 per DALY averted during the first study time horizon. The corresponding ICER for the second study period was estimated at US$1300 per DALY averted. When 85% of all excess deaths during these periods were included in the analysis, ICERs in the first and second study periods were estimated at US$1070 and US$660 per DALY averted, respectively. In the PSA, almost 100% of simulations fell below the estimated opportunity cost-based cost-effectiveness threshold for South Africa (US$2300 DALYs averted). COVID-19 vaccination programme cost per dose had the greatest impact on the ICERs. CONCLUSION: Our findings suggest that South Africa's COVID-19 vaccination programme represented good value for money in the first two years of rollout.
引用
- Edoka I, Silal S, Jamieson L, et al. A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme. Vaccine. 2024. PMID: 38824084. doi:10.1016/j.vaccine.2024.05.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。